Compare Marathon Petroleum Corp (MPC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Repligen Corporation Common Stock — how do they compare? Marathon Petroleum Corp trades at $484.92 (market cap $133.95B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Marathon Petroleum Corp is far larger — about 12× Repligen Corporation Common Stock's market cap, and Marathon Petroleum Corp pays a 0.84% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 53 Days and Repligen Corporation Common Stock for 0 Days on average.
| MPC | RGEN | |
|---|---|---|
Market Cap | $133.95B | $11.14B |
Volume | 1,644,329 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $484.92 | $194.57 |
52-Week Low | $162.63 | $102.87 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $160.47B | $11.02B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $484.92, up 5.69% today, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a reasonable P/E of 16.54. Recent news highlights refining margin strength and positive analyst sentiment, though it faces risks from potential diesel export policy shifts.
The outlook remains positive given tight refining markets and earnings growth projections, but investors should weigh policy risks and high debt levels. Wall Street consensus is strongly bullish with a $444.30 price target, though the current price exceeds this, suggesting near-term caution may be warranted despite long-term fundamentals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
